Ad is loading...
AMRN
Price
$0.52
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
96 days until earnings call
GTBP
Price
$3.01
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

AMRN vs GTBP

Header iconAMRN vs GTBP Comparison
Open Charts AMRN vs GTBPBanner chart's image
Amarin
Price$0.52
Change-$0.00 (-0.00%)
Volume$1.89M
CapitalizationN/A
GT Biopharma
Price$3.01
Change-$0.00 (-0.00%)
Volume$5.75K
CapitalizationN/A
AMRN vs GTBP Comparison Chart
Loading...
AMRN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GTBP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
AMRN vs. GTBP commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Hold and GTBP is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (AMRN: $0.52 vs. GTBP: $3.01)
Brand notoriety: AMRN: Notable vs. GTBP: Not notable
AMRN represents the Pharmaceuticals: Major, while GTBP is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMRN: 178% vs. GTBP: 27%
Market capitalization -- AMRN: $357.53M vs. GTBP: $6.73M
AMRN [@Pharmaceuticals: Major] is valued at $357.53M. GTBP’s [@Biotechnology] market capitalization is $6.73M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRN’s FA Score shows that 0 FA rating(s) are green whileGTBP’s FA Score has 0 green FA rating(s).

  • AMRN’s FA Score: 0 green, 5 red.
  • GTBP’s FA Score: 0 green, 5 red.
According to our system of comparison, GTBP is a better buy in the long-term than AMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRN’s TA Score shows that 4 TA indicator(s) are bullish while GTBP’s TA Score has 4 bullish TA indicator(s).

  • AMRN’s TA Score: 4 bullish, 5 bearish.
  • GTBP’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AMRN is a better buy in the short-term than GTBP.

Price Growth

AMRN (@Pharmaceuticals: Major) experienced а +0.94% price change this week, while GTBP (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.51%. For the same industry, the average monthly price growth was -7.62%, and the average quarterly price growth was +0.84%.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +4.04%.

Reported Earning Dates

AMRN is expected to report earnings on Feb 26, 2025.

GTBP is expected to report earnings on May 13, 2024.

Industries' Descriptions

@Pharmaceuticals: Major (-1.51% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRN($358M) has a higher market cap than GTBP($6.84M). AMRN YTD gains are higher at: -39.667 vs. GTBP (-60.654). GTBP has higher annual earnings (EBITDA): -12.35M vs. AMRN (-50.7M). AMRN has more cash in the bank: 321M vs. GTBP (6.42M). GTBP has less debt than AMRN: GTBP (0) vs AMRN (8.74M). AMRN has higher revenues than GTBP: AMRN (307M) vs GTBP (0).
AMRNGTBPAMRN / GTBP
Capitalization358M6.84M5,236%
EBITDA-50.7M-12.35M411%
Gain YTD-39.667-60.65465%
P/E Ratio67.11N/A-
Revenue307M0-
Total Cash321M6.42M5,002%
Total Debt8.74M0-
FUNDAMENTALS RATINGS
AMRN vs GTBP: Fundamental Ratings
AMRN
GTBP
OUTLOOK RATING
1..100
5824
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9199
PRICE GROWTH RATING
1..100
8642
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GTBP's Valuation (40) in the null industry is somewhat better than the same rating for AMRN (92) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew somewhat faster than AMRN’s over the last 12 months.

GTBP's Profit vs Risk Rating (100) in the null industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew similarly to AMRN’s over the last 12 months.

AMRN's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as GTBP (99) in the null industry. This means that AMRN’s stock grew similarly to GTBP’s over the last 12 months.

GTBP's Price Growth Rating (42) in the null industry is somewhat better than the same rating for AMRN (86) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew somewhat faster than AMRN’s over the last 12 months.

GTBP's P/E Growth Rating (100) in the null industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew similarly to AMRN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRNGTBP
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
AMRN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GTBP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APDWX10.850.07
+0.65%
Artisan Value Income Advisor
BRGNX38.340.24
+0.63%
iShares Russell 1000 Large-Cap Idx Instl
CFWCX27.840.17
+0.61%
Calvert Global Water C
HSWTX17.870.06
+0.34%
Hartford Schroders International Stk R5
MGFNX10.130.01
+0.10%
MassMutual Global R3

AMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with KZR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then KZR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRN
1D Price
Change %
AMRN100%
+6.17%
KZR - AMRN
56%
Loosely correlated
+1.74%
CNTB - AMRN
55%
Loosely correlated
-5.70%
HRTX - AMRN
44%
Loosely correlated
-5.36%
MGNX - AMRN
44%
Loosely correlated
-2.13%
ALXO - AMRN
43%
Loosely correlated
+6.61%
More

GTBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with PTCT. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then PTCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBP
1D Price
Change %
GTBP100%
-5.64%
PTCT - GTBP
35%
Loosely correlated
+2.22%
AMRN - GTBP
33%
Poorly correlated
+6.17%
MDGL - GTBP
32%
Poorly correlated
+3.83%
VKTX - GTBP
31%
Poorly correlated
+0.19%
BPMUF - GTBP
29%
Poorly correlated
N/A
More